Breaking News
Investing Pro 0
Black Friday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Bluebird bio's blood disorder therapy effective - FDA staff

Stock Markets Jun 07, 2022 11:22AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

By Mrinalika Roy

(Reuters) - Bluebird bio's blood disorder treatment demonstrates "clinically meaningful" benefit in patients, staff reviewers at the U.S. Food and Drug Administration said in briefing documents published on Tuesday.

The company has applied for approval of beti-cel as a one-time gene therapy for the treatment of Beta-thalassemia patients dependent on blood transfusions.

Data provided supports the effectiveness of beti-cel in these patients, the staff said https://www.fda.gov/media/159009/download, sending the company's shares up 12% to $3.34. Through Monday's close, the stock has slumped about 70% this year following regulatory setbacks.

The reviewers also published documents https://www.fda.gov/media/159010/download for bluebird's other gene therapy, eli-cel, for treating a rare neurological disease called cerebral adrenoleukodystrophy in patients below 18 years, raising safety concerns.

It is unclear whether the treatment's benefit outweighs the significant and unknown long-term risk of myelodysplastic syndrome (MDS), the reviewers wrote. The agency put the program on clinical hold last year after three trial patients developed MDS, a type of cancer.

There was a causal relationship between the treatment and two of the cases, the reviewers said on Tuesday, adding longer follow-up will uncover additional cases.

In response, bluebird said totality of the data made a clear case for eli-cel's efficacy.

A panel of FDA's outside experts is scheduled to discuss approval of the treatments later this week.

It will mark a defining moment for gene therapy for it would be the first time the Cellular, Tissue, and Gene Therapies Advisory Committee has met since 2017. The panel had then recommended approval of the first U.S. gene therapy - Spark Therapeutics' Luxturna.

The meeting's outcome is also seen as critical for bluebird after the company in March flagged "going concern" doubts.

"The company is in a very precarious financial position now, given cash runway...(the decision) is not only big for the gene therapy space, but pivotal for the company as well," William Blair analyst Raju Prasad told Reuters.

Bluebird bio's blood disorder therapy effective - FDA staff
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email